In thyroid cancer, Lee and colleagues found that pan-Trk IHC showed high specificity but moderate sensitivity for NTRK fusion-driven PTCs, due to the presence of false-negative staining in 5 out of 12 NTRK-rearranged tumors (41.7%) [18]. This evidence concerns the gene NTRK1 and thyroid cancer.